Heart risk prediction for cancer patients on certain chemotherapies
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled for a heart check-up before starting chemotherapy with anthracyclines or HER2-targeted therapies.
- Your follow-up will be done at the same center where your first heart evaluation is performed for at least 12 months.
- You have French national health insurance (Sécurité Sociale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
This trial uses detailed heart imaging (a special MRI scan) to see how chemotherapy may have affected your heart and to predict who could develop heart failure later. If you qualify, it may help your care team better monitor your heart health over time.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
This study tests a new tool that helps doctors figure out your risk for heart problems after cancer treatment. If you join, you'll get a heart risk check and possibly see a heart specialist. This could help prevent heart issues later.
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
This trial tests whether a personalized, risk-based heart care plan can help prevent heart failure in people who had certain cancer treatments. It focuses on monitoring and guiding treatment, using heart ultrasound results and other health factors.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.